Press release
Recurrent Glioblastoma Multiforme (GBM) Treatment Market is Projected to Grow Steadily During (2016-2022)
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure, nausea, headache, hemiparesis and memory loss are some of the common symptoms observed in the patients suffering from GBM. GBM is most commonly found in male with the age of 65 years and above.Alcohol consumption and malaria are the possible risk factors for the development of GBM. In addition, neurofibromatosis, tuberous sclerosis, von-hippel-lindau disease, Li-fraumeni syndrome and turcot syndrome are some of the genetic disorders that are associated with increasing incidences of gliomas. Glioblastoma multiforme is a World Health Organization Grade IV tumor that represents 15 to 20% of all primary intracranial tumors.
Request for Report TOC @ https://www.persistencemarketresearch.com/toc/10112
Increasing habits of alcohol consumption, changing lifestyle and increasing incidence of seizure are some of the drivers for the growth of GBM market. GBM is generally treated by first surgically removing the tumor then treating with chemotherapy and radiation. While this treatment plan is the currently accepted standard of care, it does not effectively prevent tumor recurrence, which ultimately causes death in GBM patients. This factor is expected to be the prime restraint for the growth of recurrent glioblastoma multiforme market.
Primary treatment involves surgery to achieve tumor debulking, followed by a multimodal regimen of radiotherapy and chemotherapy. Chemotherapy can be added to radiotherapy for patients with unfavorable low-grade glioma to improve progression free survival. The most frequently used chemotherapy regimens are a combination of procarbazine, lomustine and vincristine, or single-agent treatment with carmustine or lomustine. Temozolomide is recommended by NICE as an option for the treatment of newly diagnosed GBM. Concomitant and adjuvant chemotherapy with temozolomide given during and after radiotherapy improves survival. This drug used along with chemotherapy or radiotherapy has led to the growth of GBM treatment market to a great extent.
Region wise, the global recurrent glioblastoma multiforme (GBM) market is classified into regions namely, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominates the global GBM market owing to rising awareness, population aging, changing lifestyle and increasing healthcare awareness accentuates the growth of GBM market in these regions. In addition, Asia-Pacific region is expected to be an emerging market due to increasing demand for better healthcare facilities.
Request for Report Sample @ https://www.persistencemarketresearch.com/samples/10112
Some of the companies competing in recurrent glioblastoma multiforme (GBM) treatment market are Astrazeneca, F. Hoffman-La Roche, Ltd., GlaxoSmithKline plc., Merck & Co., Inc., Pfizer, Inc., AngioChem, Inc. Vascular Biogeneics and others.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.
Contact Us
Persistence Market Research
305 Broadway,7th Floor
New York City, NY 10007
United States
Tel: +1-646-568-7751
Tollfree: +1 800-961-0353
Email: sales@persistencemarketresearch.com
Website: https://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Recurrent Glioblastoma Multiforme (GBM) Treatment Market is Projected to Grow Steadily During (2016-2022) here
News-ID: 785702 • Views: …
More Releases from Persistence Market Research

Global Supply Chain Management BPO Market to Reach US$ 58 Bn by 2032
The Supply Chain Management BPO Market is experiencing a transformative phase as businesses increasingly recognize the strategic advantages of outsourcing non-core supply chain operations. The global market is forecast to grow at a CAGR of 8.6%, expanding from US$32.5 billion in 2025 to reach approximately US$58 billion by 2032. Supply chain management business process outsourcing (BPO) refers to the practice of delegating comprehensive supply chain operations-ranging from procurement, logistics, inventory…

Healthcare Cloud Computing Market to Reach US$ 197.4 Bn by 2032 at 17.3% CAGR
Overview of the Healthcare Cloud Computing Market
The global healthcare cloud computing market is poised for significant expansion, with an estimated valuation of US$63.5 billion in 2025, projected to reach US$197.4 billion by 2032 at a robust CAGR of 17.3%. This rapid growth is largely fueled by the increasing adoption of cloud infrastructure to enhance data accessibility, facilitate telehealth services, and integrate artificial intelligence (AI) into healthcare analytics. Healthcare organizations are…

Global Big Data Storage Market to Grow at 13% CAGR Through 2032
The global storage in big data market is undergoing a transformative expansion as organizations generate and process massive volumes of data from diverse sources such as IoT devices, digital transactions, and connected platforms. The market is projected to be valued at US$63.4 billion in 2025 and is anticipated to reach US$132 billion by 2032, registering an impressive CAGR of 13% during the forecast period (2025-2032). This growth is primarily driven…

U.S. Internet of Things (IoT) Market to Reach $609.2 Billion by 2032, Driven by …
The U.S. Internet of Things (IoT) market is experiencing rapid growth, driven by accelerating digital transformation across industries and increasing adoption of connected devices. Valued at US$ 142.2 billion in 2024, the market is expected to reach US$ 169.0 billion in 2025 and further expand at an impressive CAGR of 20.1% to reach US$ 609.2 billion by 2032. The United States currently accounts for nearly 20% of the global IoT…
More Releases for GBM
Glioblastoma Multiforme (GBM) Treatment Market Report 2024: Trends and Projectio …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.66 billion In…
Goodpasture Syndrome (Anti-GBM Disease) With Excellent CAGR 5.30%
Goodpasture Syndrome Treatment market analysis report is a professional and a detailed market study focusing on primary and secondary drivers, market share, leading segments, and geographical analysis. This market report is a comprehensive background analysis of the ABC industry, which includes an assessment of the parental market. The report also aids in prioritizing market goals and attain profitable business. This analysis gives an examination of various segments that are relied…
Anti-GBM Autoantibody Disease Market - Embracing Immune Harmony: Anti-GBM Autoan …
Newark, New Castle, USA - new report, titled Anti-GBM Autoantibody Disease Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Anti-GBM Autoantibody Disease market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Anti-GBM Autoantibody Disease market. The report offers an overview of…
Glioblastoma Multiforme Treatment (GBM) Market: Trends, Opportunities & Regional …
The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and…
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis
Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is…